And so, while one might presume that Watson can generate a correct answer for optimal management for the next systemic therapy for someone with progressing advanced lung cancer, at best Watson can reproduce the thought processes of its very limited number of mentors.

FORBES: Is IBM's Watson in Jeopardy? This Oncologist Thinks So!

This morning, the Food and Drug Administration announced that it had approved the AstraZeneca (nyse: AZN - news - people ) drug for treating advanced cases of non-small-cell lung cancer, which is the most common form of lung cancer in the United States.

FORBES: AstraZeneca's Big Green Light

It has released what it says are promising results to trials for its Stutent drug that may reduce advanced breast, lung and kidney cancer.

BBC: Global 30 hits highest level yet

Separately, Pfizer said that the Food and Drug Administration has approved Xalkori capsules, which the company calls the first-ever drug targeting anaplastic lymphoma kinase, or ALK, for the treatment of locally advanced or metastatic non-small cell lung cancer that is ALK-positive.

FORBES: Bristol-Myers, Pfizer Announce Positive Results; An FDA Approval for Pfizer

Most notably, we completed U.S. and Japanese filings for crizotinib in ALK-positive non-small cell lung cancer and U.S. and EU filings for axitinib in advanced renal cell carcinoma.

FORBES: Pfizer Suffers Loss Of Exclusivity, Braces Itself For Lipitor Expiration